argenx SE American Depositary Receipt (1AEA)
XHAN
Closed
Aug 21, 2026
Day's Range
875.0052 wk Range
555.00Overview - 1AEA - argenx SE American Depositary Receipt
Key Statistics
Valuation
Enterprise Value
-3.44B
P/E (Trailing)
‪42.45‬
EV / EBITDA
‪-2.79‬
Profitability
Gross Margin
‪90.42%‬
Profit Margin
‪89.14%‬
Operating Margin
‪30.88%‬
Return on Assets
‪14.88%‬
Return on Equity
‪17.64%‬
Ownership
Shares Outstanding
62.53M
Price stats
50-Day Avg
‪770.90‬
200-Day Avg
‪709.48‬
Peers - 1AEA - argenx SE American Depositary Receipt
Peer Comparison
Compared with companies in Biotechnology listed on XHAN.
- 1AEAXHANargenx SE American Depositary Receipt+34.08%52-week change42.46P/E (Trailing)‪89.14%‬Profit Margin
- 0QFXHANModerna, Inc.+82.89%52-week change-17.84P/E (Trailing)‪54.83%‬Profit Margin
- ANLXHANAnalog Devices, Inc.+32.46%52-week change69.63P/E (Trailing)‪61.46%‬Profit Margin
- BM8XHANBiomarin Pharmaceutical Inc.+14.63%52-week change31.80P/E (Trailing)‪77.72%‬Profit Margin
- BBZAXHANBB Biotech AG+0.00%52-week change5.58P/E (Trailing)—Profit Margin
- ANTHXHANBrw Stable Return Fund-2.88%52-week change—P/E (Trailing)—Profit Margin
- 22UAXHANBioNTech SE-21.70%52-week change—P/E (Trailing)—Profit Margin
Profile Summary - 1AEA - argenx SE American Depositary Receipt
About
argenx SE is a global, commercial-stage biopharmaceutical company headquartered in Amsterdam, Netherlands, specializing in antibody-based therapies for severe autoimmune diseases. The company developed and commercializes VYVGART (efgartigimod), the first approved neonatal Fc receptor (FcRn) blocker, which is now…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
